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Background. In the Balearic Islands, as in other areas of the Mediterranean basin, there is a 
significant proportion of asymptomatic Leishmania (L.) infantum-infected blood donors, who may 
represent an important threat to transfusion safety. The Balearic Islands blood bank, located in an 
area endemic for L. infantum, carried out a study of donors and patients to investigate the impact of 
this infectious disease on blood safety in the region. 
Materials and methods. Twenty asymptomatic Leishmania-infected blood donors were followed-
up between 2008 and 2011 to investigate the evolution of Leishmania infection in asymptomatic 
carriers. Their blood was periodically tested for anti-Leishmania antibodies by western blot and for 
Leishmania DNA by quantitative polymerase chain reaction (qPCR). Additionally, the prevalence of 
L. infantum infection was investigated in a group of 68 multiply transfused patients to ascertain the 
risk of transfusion-transmitted leishmaniasis (TTL) in the region, taking into account regular blood 
component production practices such as pre-storage leucodepletion and pathogen reduction technology.
Results. All 20 donors remained asymptomatic over the study period (2008-2011). Most donors 
had repeatedly positive qPCR results, either persistently or intermittently, but showed no symptoms 
of Leishmaniasis. Levels of parasitaemia were remarkably low in asymptomatic donors, with values 
≤1 parasite/mL. Despite multiple transfusions received over 15 years, no transfused patient studied 
was infected with L. infantum.
Discussion. L. infantum-infected donors can remain asymptomatic for at least 3 years. In our 
region, no cases of TTL were detected, despite an active search in multiply transfused patients. 
This seems to be related to two independent variables: (i) a low concentration of the parasite in the 
peripheral blood of asymptomatic carriers and (ii) the application of methods with proven efficacy 
against TTL, such as leucodepletion and pathogen reduction technology.
Keywords: Leishmania infantum, leucodepletion, pathogen reduction technology.
Introduction
Leishmaniasis is a neglected vector-borne tropical 
infection prevalent in countries in Southeast Asia, East 
Africa and Latin America, but also in some Mediterranean 
countries. In Spain, as in other countries of the 
Mediterranean basin, Leishmania infantum (L. infantum) 
is endemic and responsible for zoonotic cutaneous and 
systemic diseases, with a reservoir in the domestic dog1. 
The clinical spectrum of this protozoan infection ranges 
from asymptomatic to fatal visceral leishmaniasis. Mainly 
spread through the bite of an infected female phlebotomine 
sandfly2, the disease can also be transmitted by shared 
syringes among intravenous drug abusers3, congenitally 
from mother to infant4 and by blood transfusion5-16. Since 
most L. infantum infections are asymptomatic and resolve 
spontaneously in immunocompetent individuals, it is 
difficult to measure the blood transfusion transmission 
risk precisely. The concept of an asymptomatic carrier 
is defined as a parasite-carrying host without clinical 
manifestations. The existence of asymptomatic carriers 
is common in disease-endemic areas and may represent 
an important threat to transfusion safety.
In the Balearic Islands, a Mediterranean archipelago 
belonging to Spain, the prevalence of blood donors with 
asymptomatic Leishmania infection is high: in a screening 
of blood donors, 5.9% had L. infantum DNA and 3.1% had 
L. infantum antibodies in their blood17. These findings are 
consistent with those from other research studies performed 
in asymptomatic subjects from the Mediterranean 
basin18-27 and Brazil15,28.
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This article describes a comprehensive study of the 
risk of transfusion-transmitted leishmaniasis (TTL), 
taking a joint patient- and donor-targeted approach, 
based on our experience as a blood bank located in a 
L. infantum endemic area. First, Leishmania infection 
in donors was studied by investigating the natural 
evolution of the infection over 3 years in a selected group 
of asymptomatic blood donors living in the Balearic 
Islands. Secondly, the risk of TTL was addressed 
by studying the prevalence of L. infantum infection 
in patients in the region who had received multiple 
transfusions over a 15-year period.
Materials and methods
Donors
We studied 20 asymptomatic L. infantum-infected 
blood donors from the Balearic Islands, previously 
identified, in an epidemiological study carried out 
by our group17, by the presence of anti-Leishmania 
antibodies and/or positive quantitative polymerase 
chain reaction (qPCR) results. At present, no routine 
screening test to detect L. infantum infection in blood 
donors is in place in our region and all donors identified 
as infected during the research study were excluded 
from regular blood donation. After obtaining written 
informed consent, peripheral blood samples were 
collected from 20 donors at different intervals, based 
on the convenience of blood drives during the study, 
which was carried out between 2008 and 2011. This 
study was approved by the Balearic Island Ethics 
Committee (Study identification number: PI 10/00533; 
protocol approval number IB 1129/09). 
Patients
Sixty-eight chronic dialysis patients who received 
multiple transfusions over a 15-year period at the 
nephrology department of the "Son Llàtzer" Hospital in 
Majorca were studied in order to investigate Leishmania 
transfusion transmission. Informed consent was obtained 
from all participants. 
Sample collection
Two peripheral blood samples, one in a tube 
containing EDTA and the other without anticoagulant, 
were collected from each study participant for 
serological and molecular studies.
Serological study
Anti-Leishmania antibodies were searched for by 
western blot (WB) using a whole L. infantum antigen 
(MHOM/FR/78/LEM 75 zymodeme MON-1) as 
previously described17. A single determination was 
performed for each serum sample. The WB assay was 
performed on 0.1% SDS-13% polyacrylamide gel on a 
Mini-gel System (Bio-Rad, Hercules, CA, USA). Sera 
diluted 1:50 were assayed and a protein A horseradish 
peroxidase conjugate (1:1,000 dilution) was used. We 
considered serum to be positive when immunoreactivity 
against the 14 and/or 16 kDa L. infantum antigen fraction 
was observed.
Real-time quantitative polymerase chain reaction
DNA was extracted from 200 µL of peripheral 
blood mononuclear cells in triplicate using a High Pure 
PCR Template Preparation Kit (Roche, Mannheim, 
Germany). The presence of Leishmania spp. DNA 
was analysed by amplification of a kinetoplast DNA 
sequence by a real-time qPCR with a labelled Taq probe29 
(Bio-Rad). Positive controls (DNA from L. infantum 
MHOM/ES/04/BCN-61) and negative controls were 
included in each PCR analysis. A standard curve was 
constructed with 1:10 serial dilutions of total DNA 
extracted from L. infantum (1×105-0.1 parasite/mL). The 
parasitic load in parasite equivalents/mL of every sample 
was calculated using 7700 SDS 2.3 software (Applied 
Biosystems, Foster City, CA, USA). Each amplification 
was performed in triplicate in an ABI Prism 7700 system 
(Applied Biosystems). qPCR was considered positive 
for Leishmania when the threshold cycle (tC) was <45.
Results
Follow-up of asymptomatic L. infantum-infected 
blood donors from the Balearic Islands
The infectious status of 20 asymptomatic L. 
infantum-infected blood donors was studied in 2008-
2011. The infections had been diagnosed in a previous 
research study by the presence of anti-Leishmania 
antibodies and/or positive qPCR results. Fourteen out 
of these 20 donors agreed to be monitored at different 
intervals. In the follow-up, peripheral blood samples 
were tested by WB and qPCR.
Thirteen out of 20 donors tested positive by WB, 
with bands of 14 and 16 kDa. Nine out of the 13 donors 
who were WB-positive were followed up over periods 
ranging from 2 months to 33 months. The WB test was 
persistently positive in seven out of nine during the 
follow-up period, whereas it was negative in two donors 
(donors 2 and 6) after 23 and 25 months of the follow-up 
period, respectively (Table I).
Fourteen out of 20 donors tested positive by qPCR. 
Half of them had a positive WB at least once during the 
study period. However, the remaining seven had negative 
WB results at all times in the study. Six out of 20 donors 
tested negative by qPCR but positive by WB (Table II). 
The qPCR results were persistently positive in 
three out of the 14 donors, intermittently positive in 
eight, and three donors tested positive at least once 
during the follow-up period (Table III). In general, the 
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Table I  - Results of the qPCR and WB assays in 20 asymptomatic Leishmania infantum-infected blood donors at different 
intervals during the study period.
Donors Age 
(years)
Gender Date Western blot Peripheral blood qPCR Contact with animals
Donor 1 52 Male October-08
November-10
March-11
POS 16
POS 16
POS 14, 16
POS*
POS*
POS*
Daily contact with dogs (a dog at home) 
Had a dog that died of leishmaniasis
Donor 2 44 Female October-08
November-10
POS 14, 16 
NEG
POS*
POS*
Daily contact with dogs with leishmaniasis
Works as a veterinarian
Donor 3 26 Male October-08
March-10
NEG
NEG
POS*
NEG
Daily contact with dogs (a dog at home)
Donor 4 28 Male November-08
March-10
NEG
NEG
POS*
NEG
Daily contact with dogs (a dog at home)
Donor 5 49 Male January-09
March-10
NEG
NEG
POS*
NEG
Daily contact with dogs (two dogs at home)
Had a dog that died of leishmaniasis
Donor 6 35 Female February-09
June-09
November-10
NEG
POS 14, 16
NEG
POS**
NEG
NEG
Daily contact with dogs (a dog at home)
Works as a housekeeper in a country house 
with dogs
Donor 7 55 Male February-09
March-10
NEG
NEG
POS*
NEG
No data
Donor 8 40 Male February-09
May-09
November-10
March-11
NEG
NEG
NEG
NEG
POS**
NEG
POS**
POS**
Daily contact with dogs (a dog and a cat 
at home)
Donor 9 47 Male June-09
March-10
October-10
POS 14, 16
POS 14, 16
POS 14, 16
POS*
NEG
POS*
Daily contact with dogs (a dog at home)
Donor 10 55 Male October-09
January-10
POS 14, 16
POS 14, 16
NEG
POS*
Currently no contact with dogs
Owned a dog in the past
Donor 11 49 Male August-09
October-09
POS 16 w
POS 14
POS*
NEG
Daily contact with dogs (a dog at home)
Had a dog that died of leishmaniasis
Donor 12 60 Male August-09
October-09
POS 14, 16
POS 14, 16
NEG
NEG
No contact with dogs (a cat at home)
Donor 13 42 Female August-09
October-09
POS 14, 16
POS 14, 16
NEG
NEG
Daily contact with dogs (a dog at home)
Had a dog that died of leishmaniasis
Donor 14 43 Male October-11 NEG POS* No data
Donor 15 43 Male September-11 NEG POS* No dog at home
Donor 16 55 Female June-11 POS 14 POS* Had three dogs that died of leishmaniasis
Donor 17 49 Male October-08
July-11
POS 14, 16
POS 14, 16
NEG
NEG
Occasional contact with dogs
Donor 18 33 Male September-11 POS 14 NEG No dog at home
Family dog died of leishmaniasis
Donor 19 64 Male October-11 POS 14 NEG Daily contact with dogs (two dogs at home)
Donor 20 42 Female October-11 POS 14, 16 NEG Daily contact with dogs (two dogs at home)
qPCR: quantitative polymerase chain reaction; WB: western blot; POS*: ≤0.1 parasite equivalent/mL; POS**: 1 parasite equivalent/mL; POS 14, 16: 
WB positive with 14 and 16 kDa bands; POS 14: WB positive with a 14 kDa band; POS 16: WB positive with a 16 kDa band; POS 16 w: WB weakly 
positive with 16 kDa band.
Table II - General results of qPCR and WB tests of 20 asymptomatic Leishmania infantum-infected blood donors from Mallorca.
qPCR results WB results
Positive Negative Total
Positive 7 7 14
Negative 6 0 6
Total 13 7 20
qPCR: quantitative polymerase chain reaction; WB: western blot.
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quantification of L. infantum DNA in peripheral samples 
taken from blood donors was ≤1 parasite equivalent/mL, 
and the mean was 0.1 parasite equivalent/mL.
All the studied donors lived in rural areas of Majorca, 
and 16 of them had, or used to have, regular contact with 
dogs, either because they owned or worked with dogs. None 
of them had clinical symptoms of leishmaniasis, i.e., they 
remained asymptomatic throughout the follow-up period.
Prevalence of L. infantum infection in patients on 
chronic dialysis
Sera and peripheral whole blood from 68 patients from 
Majorca on chronic dialysis were collected for molecular 
and serological studies. Sixty patients were treated with 
haemodialysis and eight with peritoneal dialysis. 
Forty patients (58.8%) were transfused whereas 
the other 28 patients (41.2%) did not receive any 
transfusions at all during their evolution. Twenty-six 
out of the 40 transfused patients (65%) were transfused 
after the implementation of universal leucodepletion in 
2000 in our region. The remaining 14 patients (35%) 
received blood before 2000. Serology was positive 
in two patients who had not been transfused. Parasite 
DNA was not detected in any of the samples from either 
transfused or non-transfused patients. The prevalence of 
L. infantum antibodies was 0% (95% confidence interval 
[CI]: 0-10.4%) and 7.1% (95% CI: 0.9-23.7%) in the 
transfused and non-transfused patients, respectively. 
The total seroprevalence of L. infantum infection in 
haemodialysis patients was 2.9% (95% CI: 0.2-10.7%), 
which is in agreement with the finding of a previous 
study carried out by our group on blood donors in the 
Balearic Islands in which L. infantum antibodies were 
detected in 3.1% of blood donors tested (Table IV)17.
Discussion
The risk of TTL associated with asymptomatic 
Leishmania-infected blood donors is a subject of 
controversy30. Most research on the prevalence of 
asymptomatic blood donors has been conducted in 
southern European countries, and the studies have found 
a wide range of values from 0 to 36.4%, depending on 
the assay used and the number of subjects tested17-27. 
The proportion of asymptomatic Leishmania-
infected blood donors in the Balearic Islands has been 
reported previously by our group: L. infantum DNA was 
detected in the blood of 5.9% of tested blood donors and 
L. infantum antibodies were identified in 3.1%17. The 
percentages with positive PCR (10.5%) and L. infantum 
antibodies (6.8%) were higher among donors from rural 
areas in Majorca than the average value for the whole 
sample of donors. These results correlate with those of 
a recent study on asymptomatic Leishmania infection 
among blood donors in southeast Spain, in which PCR 
and enzyme-linked immunosorbent assay (ELISA) 
tests were positive in 8 and 2%, respectively, of the 
study sample. Notably, the percentage of positive PCR 
results was also much higher in rural areas (18%) than 
in larger communities (3%), and was strongly related 
to dog ownership27.
From a strict point of view, only direct methods, 
such as microscopic examination, culture or PCR, 
which show L. infantum parasites can be used for 
establishing asymptomatic carriership30. PCR assay 
can be considered as a true direct method for detecting 
the parasite, as recent investigations demonstrated 
that Leishmania nucleic acids detected by PCR came 
from living parasites and were quickly degraded after 
the parasites' death31. However, indirect methods for 
detecting asymptomatic carriers have also been used, 
such as the lesihmanin skin test and antibody detection 
by various techniques including ELISA and WB. 
Several studies have demonstrated that the detection of 
antibodies against 14-16 kDa L. infantum antigens by 
WB is generally more sensitive and specific than ELISA 
with crude antigens19,22,32. The sporadic but repeatedly 
positive WB results observed over time in some 
individuals living in endemic areas could be explained 
by an asymptomatic infection rather than by cycles of 
infection followed by total parasite clearing18,32. 
Table III - Follow-up peripheral blood qPCR results.
Number of positive results qPCR negative
Persistently positive Intermittently positive At least 1 qPCR positive 
Peripheral blood qPCR 3 8 3 6
qPCR: quantitative polymerase chain reaction.
Table IV - Leishmania infantum infection status in chronic dialysis patients.
Transfused patients (n.) Non-transfused patients (n.) Total (n.)
Patients 40 28 68
WB positive 0 2 2
qPCR positive 0 0 0
Prevalence 0% 7.1% 2.9%
qPCR: quantitative polymerase chain reaction; WB: western blot. 
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All 20 blood donors who tested positive by qPCR 
and/or WB for Leishmania were living in rural areas of 
Majorca. Sixteen of them either had, or used to have, 
contact with dogs, mostly as owners or at work. Seven 
out of the 16 had contact with a dog that had died of 
leishmaniasis, which is not surprising since Majorca is 
an area in which canine leishmaniasis is endemic and in 
some rural areas the prevalence of Leishmania infection 
in dogs, calculated from the detection of anti-Leishmania 
antibodies and/or by PCR, is between 58 and 67%. The 
prevalence of infection in dogs is much higher than the 
prevalence of overt Leishmania-related disease33,34. 
More than 50% of infected dogs, the main reservoir 
hosts of L. infantum, are asymptomatic carriers and can 
easily infect sandflies. However, people co-infected with 
this parasite and human immunodeficiency virus are also 
highly infectious to sandflies and may play a role in the 
transmission of the parasitic infection in some areas2, 
so the impact of asymptomatically infected carriers on 
the natural transmission cycle is currently not known.
All 20 blood donors remained asymptomatic over the 
3-year study period, and most of them repeatedly tested 
positive by qPCR, either persistently or intermittently. It 
is unclear whether they became re-infected every year 
during the active phase of the phlebotomine sandfly 
cycle, or whether they had persistent infections that were 
being controlled by their immune system. The levels 
of parasitaemia were remarkably low in asymptomatic 
blood donor carriers (mean: 0.1 parasite equivalent/mL) 
compared to those in patients with visceral leishmaniasis 
(50 parasites/mL)35. 
The control mechanisms by which L. infantum 
carriers with subclinical infection manage to restrain 
their infection are unknown. It has been suggested that 
interleukin-17 could play an essential role in blocking 
parasite replication, thus avoiding the development of 
visceral leishmaniasis in the infected individual36,37. 
Interestingly, it has been reported that there is a lack of 
correlation between qPCR findings and anti-Leishmania 
antibody detection in asymptomatic L. infantum carriers. 
Riera et al. previously showed that serology tests can 
undervalue the prevalence of Leishmania infection 
in blood donors17, which would be more accurately 
determined by PCR. Additionally, compared to PCR, 
culture techniques have demonstrated low sensitivity 
in asymptomatic carriers17. The absence of an antibody 
response during an asymptomatic infection, despite 
the presence of the parasite, has also been observed 
in healthy subjects with cryptic L. infantum infection 
in other endemic regions28,38-40. Currently, no routine 
screening test is used to detect Leishmania infection in 
blood donors, but should one be established, the most 
convenient assay would certainly be PCR-based.
A recent review of the risk of TTL41 using a 
classification scheme based on the criteria of the 
National Healthcare Safety Network of the Centers 
for Disease Control and Prevention42, pointed out that 
only ten individual reports in the available literature 
describe suspected transfusion-related transmission 
of Leishmania spp. in a total of 14 patients5-14; in 
addition, a seroprevalence study in Brazil investigated 
32 cases of visceral leishmaniasis diagnosed out of 
82 patients undergoing haemodialysis and multiple 
transfusions15. 
Although four possibly infected donors were identified 
in the ten reported cases, it was impossible to prove the 
presence of Leishmania spp. in any of them, either in 
the donors' peripheral blood or the transfused blood 
components. Moreover, no information on the recipients' 
Leishmania infection status prior to transfusion was 
provided in any of the reports. Given the lack of scientific 
evidence, all the cases were classified as possible, and 
none of them as definitive cases of TTL41.
The unambiguous identification of cases of TTL 
is hindered by several factors. First of all, detecting 
transfusion-related transmission is very challenging, 
especially in endemic regions in which the infection 
is mostly transmitted via the bite of phlebotomine 
sandflies. Secondly, the lack of clinical manifestations 
in infected immunocompetent subjects impedes or 
delays the diagnosis16. A prompt diagnosis of TTL is 
also prevented by the absence of data on the Leishmania 
infectious status of the patient before transfusion, the 
donor or the transfused blood component42.
The reporting of negative results regarding TTL is 
also essential, especially in endemic regions such as 
the Balearic Islands where measures to prevent TTL, 
including leucodepletion, have been in place for some 
time. Thus, in our study of chronic dialysed patients, 
no transfused patients were found to be infected. In two 
patients who had L. infantum antibodies and yet tested 
negative by PCR, blood transfusion could be ruled out 
as the cause of L. infantum infection since neither had 
received any transfusions. 
Our results differ from those of a study carried out 
in Brazil, another endemic area, which investigated 
the prevalence of anti-Leishmania antibodies among 
blood donors and multiply transfused haemodialysis 
patients15. In the Brazilian study, the seroprevalence 
was approximately 9-25% in blood donors and there 
was a high rate of positivity (37%) in dialysis patients 
who had received multiple transfusions. Although the 
authors stressed the need to consider blood transfusion 
as a possible route of Leishmania transmission in their 
region, no evidence was provided that blood transfusion 
was the real cause of the Leishmania infection in patients 
undergoing dialysis. There were no data about Leishmania 
infection status of patients prior to transfusion, which 
is essential in an endemic area, or about the donors or 
transfused blood components. It was also not stated in 
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the aforementioned study whether the transfused blood 
components were leucodepleted or not. This information 
is crucial, since it has been proven that filtration using a 
whole-blood and red blood cell leucodepletion system is 
an effective method for removing Leishmania parasites 
from blood given by asymptomatic L. infantum-infected 
donors17,26. Our negative results in multiply transfused 
patients can be explained by the implementation of red 
blood cell leucodepletion at the bedside in the Balearic 
Islands more than 20 years ago and, as in most blood 
banks in Spain, pre-storage universal leucodepletion for 
all blood components, which was introduced 15 years 
ago. Consequently, all blood components -red blood 
cells, platelets and plasma- transfused to patients in the 
Balearic Islands have been pre-storage leucodepleted 
since 2000.
In order for Leishmania to be transmitted through a 
transfusion, amastigotes must be present in the blood, 
either within monocytes or free in the plasma, and they 
must survive processing and storage conditions. Several 
pathogen reduction technologies to decrease the risk of 
TTL, besides leucodepletion, have been tested. These 
are mostly based on damaging nucleic acids, thereby 
preventing replication of the pathogen's genomes, 
and include the use of riboflavin and ultraviolet light 
(Mirasol® Pathogen Reduction Technology System; 
Terumo BCT, Lakewood, CO, USA) in plasma and 
platelets43,44, photochemical treatment by amotosalen 
plus ultraviolet light (INTERCEPT® Blood System for 
Platelets; Cerus, BV, Amersfoot, the Netherlands) in 
plasma and platelets45,46 as well as by thiopyrylium in 
red blood cell suspensions47. 
In the Balearic Islands, pathogen reduction 
technology based on amotosalen plus ultraviolet light 
for platelets was introduced in 2008. More recently, in 
2012, pathogen reduction technology based on riboflavin 
and ultraviolet light was established in our blood bank 
for treating platelets and plasma. Until now, despite an 
active and thorough investigation in patients receiving 
multiple blood components, no cases of TTL have 
been reported in our region. Both prevention strategies, 
leucodepletion and pathogen reduction technologies, 
seem to provide a sufficient level of protection against 
Leishmania infection transmitted by transfusion. A 
recent study on Leishmania donovani has clearly shown 
the very high efficacy of treating whole blood with 
pathogen reduction technology based on riboflavin and 
ultraviolet light to eliminate Leishmania48.
Conclusions
When assessing the possible transmission of 
Leishmania by blood transfusion, two key factors stand 
out: first, a significant proportion of asymptomatic blood 
donors in some endemic regions have transient and low 
parasitaemia; secondly, scientific evidence regarding the 
few TTL cases reported in the literature is scarce and 
as a result they have been classified as possible rather 
than definitive cases41. 
It is difficult to establish a case of transfusion-
transmitted Leishmania beyond any reasonable doubt. 
Not only can asymptomatic L. infantum infection in 
adults go unnoticed, but the real level of transmission 
risk may be low. This is related to the extremely low 
parasitaemia in asymptomatic carriers, along with the 
gradual implementation of different blood processing 
methods to improve blood safety, such as pre-storage 
leucodepletion and pathogen reduction technologies.
Indeed, pathogen inactivation technology using 
riboflavin and ultraviolet light to eliminate Leishmania, 
among other germs, in whole blood48 appears to be very 
promising, from both logistic and economic points 
of view. It is particularly useful in endemic regions 
in which whole blood is not usually fractioned into 
components, and in areas receiving immigrants from 
endemic regions.
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